Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2008

01-12-2008 | Original Article

Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution

Authors: Pedro M. G. Soares, José Maurício S. C. Mota, Antoniella S. Gomes, Ricardo B. Oliveira, Ana Maria S. Assreuy, Gerly Anne C. Brito, Armênio A. Santos, Ronaldo A. Ribeiro, Marcellus H. L. P. Souza

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2008

Login to get access

Abstract

Aim

To evaluate gastrointestinal motility during 5-fluorouracil (5-FU)-induced intestinal mucositis.

Materials and methods

Wistar rats received 5-FU (150 mg kg−1, i.p.) or saline. After the 1st, 3rd, 5th, 15th and 30th day, sections of duodenum, jejunum and ileum were removed for assessment of epithelial damage, apoptotic and mitotic indexes, MPO activity and GSH concentration. In order to study gastrointestinal motility, on the 3rd or 15th day after 5-FU treatment, gastric emptying in vivo was measured by scintilographic method, and stomach or duodenal smooth muscle contractions induced by CCh were evaluated in vitro.

Results

On the third day of treatment, 5-FU induced a significant villi shortening, an increase in crypt depth and intestinal MPO activity and a decrease in villus/crypt ratio and GSH concentration. On the first day after 5-FU there was an increase in the apoptosis index and a decrease in the mitosis index in all intestinal segments. After the 15th day of 5-FU treatment, a complete reversion of all these parameters was observed. There was a delay in gastric emptying in vivo and a significant increase in gastric fundus and duodenum smooth muscle contraction, after both the 3rd and 15th day.

Conclusion

5-FU-induced gastrointestinal dysmotility outlasts intestinal mucositis.
Literature
1.
Akiho H, Deng Y, Blennerhassett P, Kanbayashi H, Collins SM (2005) Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology 129:131–141PubMedCrossRef
2.
Akiho H, Khan WI, Al-Kaabi A, Blennerhassett P, Deng Y, Collins SM (2007) Cytokine modulation of muscarinic receptors in the murine intestine. Am J Physiol Gastrointest Liver Physiol 293:250–255CrossRef
3.
Annese V, Bassotti G, Napolitano G, Usai P, Andriulli A, Vantrappen G (1997) Gastrointestinal motility disorders in patients with inactive Crohn’s disease. Scand J Gastroenterol 32:1107–1117PubMedCrossRef
4.
Baerg J, Murphy JJ, Anderson R, Magee JF (1999) Neutropenic enteropathy: a 10-year review. J Pediatr Surg 34:1068–1071PubMedCrossRef
5.
Bradley PP, Christensen RD, Rothstein G (1982) Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60:618–622PubMed
6.
Carneiro-Filho BA, Oria RB, Rea KW, Brito GA, Fujii J, Obrig T, Lima AA, Guerrant RL (2004) Alanyl-glutamine hastens morphologic recovery from 5-Fluorouracil-induced mucositis in mice. Nutrition 20:934–941PubMedCrossRef
7.
De Jonge WJ, Van den Wijingard RF, The Fo ter Beek ML, Bennink RJ, Tytgat G, Buijs R, Reitsma P, Van Deventer S, Boeckxstaens G (2003) Postoperative ileum is maintained by intestinal immune infiltrates that activate inhibitory neural pathways in mice. Gastroenterology 125:1137–1147PubMedCrossRef
8.
De Winter BY, Bredenoord AJ, De Man JG, Moreels TG, Herman AG, Pelckmans PA (2002) Effect of inhibition of inducible nitric oxide synthase and guanylyl cyclase on endotoxin-induced delay in gastric emptying and intestinal transit in mice. Shock 18:125–131PubMedCrossRef
9.
Demedts I, Geboes K, Kindt S, Vanden Berghe P, Andrioli A, Janssens J, Tack J (2006) Neural mechanisms of early postinflammatory dysmotility in rat small intestine. Neurogastroenterol Motil 18:1102–1111PubMedCrossRef
10.
Denham JW, Abbott RL (1991) Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity. J Clin Oncol 9:458–463PubMed
11.
Depoortere I, Van Assche G, Thijs T, Geboes K, Peeters TL (1999) Differential changes in ACh, motilin, substance P, and K+–induced contractility in rabbit colitis. Am J Physiol Gastrointest Liver Physiol 277:61–68
12.
Du XX, Doerschuk CM, Orazi A, Williams DA (1994) A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 83:33–37PubMed
13.
Duncan M, Grant G (2003) Oral and intestinal mucositis—causes and possible treatments. Aliment Pharmacol Ther 18:853–874PubMedCrossRef
14.
Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL (1998) Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58:933–939PubMed
15.
Haba T, Sarna SK (1993) Regulation of gastroduodenal emptying of solids by gastropyloroduodenal contractions. Am J Physiol 264:G261–G271PubMed
16.
Isgar B, Harman M, Kaye MD, Whorwell PJ (1983) Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 24:190–192PubMedCrossRef
17.
Kris M, Grall R, Clark R, Tyson L, Groshen S (1998) Control of chemotherapy-induced diarrhea with synthetic enkephalin BW942C: a randomised trial with placebo in patients receiving cisplatin. J Clin Oncol 6:663–668
18.
Longley DB, Harkin D, Johnston PG (2003) 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338PubMedCrossRef
19.
Macpherson BR, Pfeiffer CJ (1978) Experimental production of diffuse colitis in rats. Digestion 17:35–50CrossRef
20.
Magne N, Marcy PY, Chamorey E, Guardiola E, Pivot X, Schneider M, Demard F, Bensadoun RJ (2001) Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: a long-term quality of life analysis. Head Neck 23:678–682PubMedCrossRef
21.
Martinolle JP, Garcia-Villar R, More J, Bueno L (1995) Evidence for mast cell, leukotriene and nitric oxide involvement in the regulation of the adrenoreceptor number of inflamed small intestine in guinea pigs. Neurogastroenterol Motil 3:187–195
22.
Moreels TG, De Man JG, Boger JJ, De Winter BY, Vrolix G, Herman AG, Van Marck EA, Pelckmans PA (2001) Effect of Schistosoma mansoni-induced granulomatous inflammation on murine gastrointestinal motility. Am J Physiol Gastrointest Liver Physiol 280:G1030–G1042PubMed
23.
Moreels TG, De Man JG, De Winter BY, Timmermans JP, Herman AG, Pelckmans PA (2001) Effect of 2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced ileitis on the motor function of non-inflamed rat gastric fundus. Neurogastroenterol Motil 13:339–352PubMedCrossRef
24.
Nelson K, Walsh D, Sheehan F (2002) Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients. Support Care Cancer 10:455–461PubMedCrossRef
25.
Orazi A, Du X, Yang Z, Kashai M, Williams DA (1996) Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 75:33–42PubMed
26.
Petschow BW, Carter DL, Hutton GD (1993) Influence of orally administered epidermal growth factor on normal and damaged intestinal mucosa in rats. J Pediatr Gastroenterol Nutr 17:49–58PubMedCrossRef
27.
Pritchard DM, Potten CS, Hickman JA (1998) The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil–induced histopathology in murine intestinal epithelia. Cancer Res 58:5453PubMed
28.
Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA (1997) Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 94:1795PubMedCrossRef
29.
Rang HP, Dale MM, Ritter JM (1999) Cancer chemotherapy. Harcourt Brace Co. Ltd., Edinburgh
30.
Ribeiro RA, Flores CA, Cunha FQ, Ferreira SH (1991) IL-8 causes in vivo neutrophil migration by a cell-dependent mechanism. Immunology 73:472–477PubMed
31.
Riezzo G, Clemente C, Leo S, Russo F (2005) The role of electrogastrography and gastrointestinal hormones in chemotherapy-related dyspeptic symptoms. J Gastroenterol 40:1107–1115PubMedCrossRef
32.
Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205PubMedCrossRef
33.
Simrén M, Vos R, Janssens J, Tack J (2003) Unsuppressed postprandial phasic contractility in the proximal stomach in functional dyspepsia: relevance to symptoms. Am J Gastroenterol 98(10):2169–2175PubMed
34.
Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43PubMedCrossRef
35.
36.
Souza MH, Troncon LE, Cunha FQ, Oliveira RB (2003) Decreased gastric tone and delayed gastric emptying precede neutrophil infiltration and mucosal lesion formation in indomethacin-induced gastric damage in rats. Braz J Med Biol Res 36:1383–1390PubMed
37.
Spiller RC (2004) Inflammation as a basis for functional GI disorders. Best Pract Res Clin Gastroenterol 18:641–661PubMedCrossRef
38.
Tack J, Demedts I, Dehondt G (2002) Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 122:1738–1747PubMedCrossRef
39.
Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J (1998) Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115(6):1346–1352PubMedCrossRef
40.
Teresi ME, Crom WR, Chui KE, Mirro J, Evans WE (1987) Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 110:788–792PubMedCrossRef
41.
Vermillion DL, Collins SM (1988) Increased responsiveness of jejunal longitudinal muscle in Trichinella-infected rats. Am J Physiol 264:G124–G129
Metadata
Title
Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution
Authors
Pedro M. G. Soares
José Maurício S. C. Mota
Antoniella S. Gomes
Ricardo B. Oliveira
Ana Maria S. Assreuy
Gerly Anne C. Brito
Armênio A. Santos
Ronaldo A. Ribeiro
Marcellus H. L. P. Souza
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0715-9

Other articles of this Issue 1/2008

Cancer Chemotherapy and Pharmacology 1/2008 Go to the issue

Original Article

Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism

Original Article

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

Original Article

Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?

Original Article

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

Original Article

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

Original Article

Antitumor activity of noscapine in human non-small cell lung cancer xenograft model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits